Canakinumab for treatment of adult onset Still's disease to achieve reduction of arthritic manifestation
Phase of Trial: Phase II
Latest Information Update: 22 May 2018
At a glance
- Drugs Canakinumab (Primary)
- Indications Adult-onset Still's disease
- Focus Therapeutic Use
- Acronyms CONSIDER
- 17 May 2018 Status changed from recruiting to discontinued.
- 19 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2021.
- 19 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.